Literature DB >> 22113988

Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohn's disease and the effect of therapy.

Yvonne Dörffel1, Alexander Swidsinski, Vera Loening-Baucke, Bertram Wiedenmann, Marianne Pavel.   

Abstract

BACKGROUND: The aims were to comparatively investigate the biostructure of colonic microbiota in patients with neuroendocrine tumors and Crohn's disease (CD) and to study the response of the microbiota to therapy.
METHODS: Sections of fecal cylinders from 66 patients with neuroendocrine tumors (NET; 25 foregut, 30 midgut, 11 hindgut), 50 patients with CD (Crohn's Disease Activity Index [CDAI] ≥150), and 30 patients with chronic idiopathic diarrhea seen at the Charité Hospital and 25 healthy controls were investigated using fluorescence in situ hybridization with probes specific for five bacterial groups: Faecalibacterium prausnitzii, Clostridium group XIVa / Roseburia group, Bacteroides, Enterobacteriaceae, and Bifidobacteriaceae.
RESULTS: We found a striking F. prausnitzii (Fprau) depletion in the stool of patients with NET of the midgut and patients with CD. The changes of the microbiota in the two other NET groups were uncharacteristic and similar to those observed in patients with chronic idiopathic diarrhea. Fprau depletion was reversible with chemotherapy and with interferon alpha-2b treatment in patients with midgut NET. Somatostatin analogs had no influence on Fprau concentrations.
CONCLUSIONS: Patients with NET and CD show similarities in their abnormalities of the fecal biostructure. Interferon alpha and systemic chemotherapy significantly improved the fecal biostructure in patients with midgut NET.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113988     DOI: 10.1002/ibd.21923

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  12 in total

Review 1.  Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics.

Authors:  Mireia Lopez-Siles; Sylvia H Duncan; L Jesús Garcia-Gil; Margarita Martinez-Medina
Journal:  ISME J       Date:  2017-01-03       Impact factor: 10.302

2.  Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii.

Authors:  Sylvie Miquel; Rebeca Martín; Chantal Bridonneau; Véronique Robert; Harry Sokol; Luis G Bermúdez-Humarán; Muriel Thomas; Philippe Langella
Journal:  Gut Microbes       Date:  2014-01-22

3.  Overrepresentation of HLA-DQ2 in small intestinal neuroendocrine tumor patients.

Authors:  Kalle Landerholm; Ursula Falkmer; Roland Persson; Najme Wall; Claes Hallert; Johannes Järhult
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 4.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 5.  Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature.

Authors:  Yuan Cao; Jun Shen; Zhi Hua Ran
Journal:  Gastroenterol Res Pract       Date:  2014-03-27       Impact factor: 2.260

6.  The fecal microbiota as a biomarker for disease activity in Crohn's disease.

Authors:  Danyta I Tedjo; Agnieszka Smolinska; Paul H Savelkoul; Ad A Masclee; Frederik J van Schooten; Marieke J Pierik; John Penders; Daisy M A E Jonkers
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

7.  Comparative analysis of Faecalibacterium prausnitzii genomes shows a high level of genome plasticity and warrants separation into new species-level taxa.

Authors:  Cormac Brian Fitzgerald; Andrey N Shkoporov; Thomas D S Sutton; Andrei V Chaplin; Vimalkumar Velayudhan; R Paul Ross; Colin Hill
Journal:  BMC Genomics       Date:  2018-12-14       Impact factor: 3.969

8.  Dynamics of metatranscription in the inflammatory bowel disease gut microbiome.

Authors:  Melanie Schirmer; Eric A Franzosa; Jason Lloyd-Price; Lauren J McIver; Randall Schwager; Tiffany W Poon; Ashwin N Ananthakrishnan; Elizabeth Andrews; Gildardo Barron; Kathleen Lake; Mahadev Prasad; Jenny Sauk; Betsy Stevens; Robin G Wilson; Jonathan Braun; Lee A Denson; Subra Kugathasan; Dermot P B McGovern; Hera Vlamakis; Ramnik J Xavier; Curtis Huttenhower
Journal:  Nat Microbiol       Date:  2018-01-08       Impact factor: 17.745

9.  The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study.

Authors:  Tomohisa Takagi; Yuji Naito; Ryo Inoue; Saori Kashiwagi; Kazuhiko Uchiyama; Katsura Mizushima; Saeko Tsuchiya; Tetsuya Okayama; Osamu Dohi; Naohisa Yoshida; Kazuhiro Kamada; Takeshi Ishikawa; Osamu Handa; Hideyuki Konishi; Kayo Okuda; Yoshimasa Tsujimoto; Hiromu Ohnogi; Yoshito Itoh
Journal:  J Clin Biochem Nutr       Date:  2017-12-12       Impact factor: 3.114

10.  Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects.

Authors:  Mireia Lopez-Siles; Núria Enrich-Capó; Xavier Aldeguer; Miriam Sabat-Mir; Sylvia H Duncan; L Jesús Garcia-Gil; Margarita Martinez-Medina
Journal:  Front Cell Infect Microbiol       Date:  2018-09-07       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.